Chaisson RE - Search Results

1

The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.

Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. Mehta SH, et al. Among authors: chaisson re. J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):577-84. doi: 10.1097/00126334-200308150-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12902801

2

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Sulkowski MS, et al. Among authors: chaisson re. Hepatology. 2002 Jan;35(1):182-9. doi: 10.1053/jhep.2002.30319. Hepatology. 2002. PMID: 11786975

3

Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors.

Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE. Oursler KK, et al. Among authors: chaisson re. Clin Infect Dis. 2002 Mar 15;34(6):752-9. doi: 10.1086/338784. Epub 2002 Feb 7. Clin Infect Dis. 2002. PMID: 11850859

4

Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic.

Lucas GM, Gebo KA, Chaisson RE, Moore RD. Lucas GM, et al. Among authors: chaisson re. AIDS. 2002 Mar 29;16(5):767-74. doi: 10.1097/00002030-200203290-00012. AIDS. 2002. PMID: 11964533

5

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: chaisson re. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

6

Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity.

Sterling TR, Chaisson RE, Moore RD. Sterling TR, et al. Among authors: chaisson re. Clin Infect Dis. 2003 Mar 15;36(6):812-5. doi: 10.1086/367934. Epub 2003 Feb 27. Clin Infect Dis. 2003. PMID: 12627368

7

Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study.

Lucas GM, Chaisson RE, Moore RD. Lucas GM, et al. Among authors: chaisson re. J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):321-8. doi: 10.1097/00126334-200307010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12843742

8

Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study.

Sterling TR, Chaisson RE, Keruly J, Moore RD. Sterling TR, et al. Among authors: chaisson re. J Infect Dis. 2003 Dec 1;188(11):1659-65. doi: 10.1086/379741. Epub 2003 Nov 14. J Infect Dis. 2003. PMID: 14639536

9

Differences in HIV disease progression by injecting drug use in HIV-infected persons in care.

Moore RD, Keruly JC, Chaisson RE. Moore RD, et al. Among authors: chaisson re. J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51. doi: 10.1097/00126334-200401010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 14707791

10

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.

Karakousis PC, Moore RD, Chaisson RE. Karakousis PC, et al. Among authors: chaisson re. Lancet Infect Dis. 2004 Sep;4(9):557-65. doi: 10.1016/S1473-3099(04)01130-2. Lancet Infect Dis. 2004. PMID: 15336223 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

456 results

Search Page

Filters